Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs....

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten, Albert Torri
Format: Artigo
Langue:Inglês
Publié: Adis, Springer Healthcare 2019-05-01
Collection:Rheumatology and Therapy
Sujets:
Arthritis
Biological DMARDs
Rheumatoid arthritis
Accès en ligne:http://link.springer.com/article/10.1007/s40744-019-0157-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Chargement en cours...

Documents similaires